Delivering the COVID-19 vaccine worldwide

Posted By: Uwe MedActiv In: Sub Category 1 On: Comment: 0 Hit: 526

The delivery of the new COVID-19 vaccines presents huge technical challenges. Whether it is international transport, or simply “last-mile” delivery to the recipient of the vaccine, the challenge of transporting large amounts of vaccines at preset temperatures is complicated. “Delivering 7.5 billion doses of vaccine globally is a challenge of epic proportions. Of course, you have to consider the logistics of delivery in different areas or countries, but the «last mile challenge» of delivering a vaccine that needs to be kept at a temperature between 2 and 8°C in places that do not have the necessary infrastructure for safe transport and delivery will always remain an issue”, says Dr Olaf DIEGEL, Director of R&D at MedActiv.

The delivery of the new COVID-19 vaccines presents huge technical challenges. Whether it is international transport, or simply “last-mile” delivery to the recipient of the vaccine, the challenge of transporting large amounts of vaccines at preset temperatures is complicated. “Delivering 7.5 billion doses of vaccine globally is a challenge of epic proportions. Of course, you have to consider the logistics of delivery in different areas or countries, but the «last mile challenge» of delivering a vaccine that needs to be kept at a temperature between 2 and 8°C in places that do not have the necessary infrastructure for safe transport and delivery will always remain an issue”, says Dr Olaf DIEGEL, Director of R&D at MedActiv. The World Health Organization estimates that up to 47% of vaccines are denatured in some way during the “last-mile” of delivery.

The COVID-19 vaccine will be available in three different formulations requiring different temperature ranges:

1)   The Pfizer/BioNTech vaccine needs to be transported at -70°C; but can be kept at a temperature between 2 and 8°C for up to 5 days for “last-mile” delivery and use.

2)   The Moderna vaccine needs to be transported at -20°C; but can be kept at a temperature between 2 and 8°C for up to 30 days for “last-mile” delivery and use.

3)   Most other vaccines will be stored and transported at a temperature between 2 and 8°C.

MedActiv, a French company created in 2008, is a worldwide leader in the manufacturing of isothermal solutions for the pharmaceutical industry. Lifeina is a French company that has created the world’s smallest fridge for the safe transport of medication. These two companies have joined forces to produce a full range of products for the transport of the COVID-19 vaccine.

No alt text provided for this image

iCool VacPack

For the transport of single or smaller quantities of vaccines by individuals or private healthcare professionals.

• 18 hours between 2 and 8°C

• Cavity size: 18 x 7 x 7cm

• Contains 24 vials of vaccines

iCool MediCube

No alt text provided for this image

For the transport of daily quantities of vaccines by healthcare professionals who need to be mobile to vaccinate patients in remote areas (old-age home).

• 36 hours between 2 and 8°C

• Cavity size: 18 x 9 x 14cm

• Contains 72 vials of vaccines

BioBag

No alt text provided for this image

For the transport of larger quantities of vaccines by healthcare professionals.

• 60 hours between -25 and -15°C

• 92 hours between 2 and 8°C

• Cavity size: 20 x 20 x 20cm

• Contains 108 vials of vaccines

Vaccine Box PRO (also available as a disposable product)

No alt text provided for this image

Reuseable secure packaging for the transport of larger quantities of vaccines for delivery to local distribution centers.

• 100 hours between 2 and 8°C

• Cavity size: 35 x 20 x 20cm

• Contains 400 vials of vaccines

The MedActiv/Lifeina solutions use SAP (Super Absorbent Polymers) that were specially developed by MedActiv as phase change materials. A phase change material (PCM) is a substance which releases sufficient energy at phase transition to provide useful cooling. The MedActiv gel packs will generate cold while transiting from solid to liquid format. They are frozen after 8 hours at -18°C but after 12 hours of freezing time they will enter a new phase and stay frozen for three times longer. They are compact, insensitive to motion or tilting, have no moving parts, and simply need to be frozen in a standard household refrigerator at -18°C for 12 hours.

As leaders in the development of solutions for thermosensitive medication, MedActiv and Lifeina are playing an important role in the management of COVID-19 vaccines worldwide. “When we first imagined the world’s smallest fridge back in 2008, we had not yet realized how important our business would become. Today I am proud that we are helping millions of people worldwide to be vaccinated against the COVID-19 virus. Our entire organization has now been re-focused on finding solutions for the transport and delivery of the COVID-19 vaccine” says Uwe DIEGEL, CEO of Lifeina

Contact

Lifeina

Attention : Uwe DIEGEL, CEO

6 rue de Castellane, 75008, Paris, France

Tel: 0142661559

hello@lifeina.com

Comments

Leave your comment